Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 19/20 | 0.56 |
| ▸ | APP | P05067 | 7/20 | 0.56 |
| ▸ | CTSD | P07339 | 5/20 | 0.48 |
| ▸ | CTSB | P07858 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1990774 | 0.81 | KDM1A (0.42) | BACE1APPCTSD | |
| SCHEMBL1992787 | 0.80 | BACE1 (0.48) | BACE1 | |
| SCHEMBL12565340 | 0.80 | BACE1 (0.48) | BACE1APPCTSDMAPT | |
| SCHEMBL7940159 | 0.80 | BACE1 (0.34) | BACE1APPCTSDNPC1MAPT | |
| SCHEMBL1993405 | 0.78 | BACE1 (0.54) | BACE1APPCTSDKCNH2 | |
| SCHEMBL1991931 | 0.77 | BACE1 (0.53) | BACE1CTSDCTSB | |
| SCHEMBL1996400 | 0.76 | BACE1 (0.42) | BACE1APPCTSDKCNH2 | |
| SCHEMBL1992797 | 0.75 | BACE1 (0.38) | BACE1CTSDNPC1MAPTRAB9A | |
| SCHEMBL1994163 | 0.73 | BACE1 (0.64) | BACE1APPKCNH2 | |
| SCHEMBL427996 | 0.73 | BACE1 (0.50) | BACE1APPCTSDCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318416-B1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-8501733-B2 | Spiroaminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8501733-B2 | Spiroaminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8501733-B2 | Spiroaminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20110152253-A1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20110152253-A1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20110152253-A1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152253-A1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | BACE1 1/4885APP 3/4885CTSD 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.